findmyKOL

Arash Mostaghimi, MD, MPA, MPH

Basic profile

Brigham and Women's Hospital

ORCIDNPI
RegionBoston, MA · NortheastSpecialtyDermatologyFocusDermatology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Arash Mostaghimi is a Dermatology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 523 publications with 7,290 citations (h-index 44). By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
523publications

Distinct works indexed by OpenAlex, matched via ORCID.

7,290citations

Total citations across indexed works.

44h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
77companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

77 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

77 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    37.4%
    Azole Antifungal22.6%
    Ketoconazole71%Fluconazole29%
    Part D<11 patients
    Tetracycline-class Drug6%
    Doxycycline Monohydrate100%
    Part D<11 patients

    + 2 more classes in this area

  • Dermatology

    17.1%
    Corticosteroid12.9%
    Triamcinolone Acetonide100%
    Part D28 patients
    Interleukin-4 Receptor alpha Antagonist4.3%
    Dupixent Pen100%
    Part D<11 patients
  • Cancer & immunology

    16.3%
    TNF inhibitor6.3%
    Humira Pen100%
    Part D<11 patients
    Retinoid3.4%
    Tretinoin100%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)6.3% facility · 93.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”